Evidence map›Paper›PMID 30542718›Full record

ArticleOncology reports2018

Downregulation of miR‑224‑5p in prostate cancer and its relevant molecular mechanism via TCGA, GEO database and in silico analyses.

Bin-Liang Gan, Li-Jie Zhang, Li Gao, Fu-Chao Ma, Rong-Quan He, Gang Chen, Jie Ma, Jin-Cai Zhong, Xiao-Hua Hu

Open access · bronzeAbstract read
In one paragraph

Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. miR-224 targets3 Biotech · 2020
    Article
  12. Review
  13. The miRNAs Role in Melanoma and in Its Resistance to Therapy.International journal of molecular sciences · 2020
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Bin-Liang GanDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Li-Jie ZhangDepartment of Ultrasound, First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Li GaoDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Fu-Chao MaDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Rong-Quan HeDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Gang ChenDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Jie MaDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Jin-Cai ZhongDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Xiao-Hua HuDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The function of the expression of microRNA (miR)‑224‑5p in prostate adenocarcinoma (PCa) remains to be elucidated, therefore, the present study aimed to investigate the clinical significance and potential molecular mechanism of miR‑224‑5p in PCa. Data on the expression of miR‑224‑5p in PCa were extracted from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), ArrayExpress and previous literature, and meta‑analyses with standardized mean difference (SMD) and summary receiver operating characteristic (sROC) methods were performed for statistical analyses. The prospective target genes of miR‑224‑5p were collected by overlapping the differentially expressed mRNAs in TCGA and GEO, and target genes predicted by miRWalk2.0. Subsequently, in silico analysis was performed to examine the associated pathways of miR‑224‑5p in PCa. The expression of miR‑224‑5p was markedly lower in PCa; the overall SMD was ‑0.562, and overall sROC area under the curve was 0.80. In addition, Kyoto Encyclopedia of Genes and Genomes analysis revealed that the prospective target genes of miR‑224‑5p were largely enriched in the amino sugar and nucleotide sugar metabolism signaling pathway, and three genes [UDP‑N‑acetylglucosamine pyrophosphorylase 1 (UAP1), hexokinase 2 (HK2) and chitinase 1 (CHIT1)] enriched in this pathway showed higher expression (P<0.05). In addition, key genes in the protein‑protein interaction network analysis [DNA topoisomerase 2‑α (TOP2A), ATP citrate lyase (ACLY) and ribonucleotide reductase regulatory subunit M2 (RRM2)] exhibited significantly increased expression (P<0.05). The results suggested that the downregulated expression of miR‑224‑5p may be associated with the clinical progression and prognosis of PCa. Furthermore, miR‑224‑5p likely exerts its effects by targeting genes, including UAP1, HK2, CHIT1, TOP2A, ACLY and RRM2. However, in vivo and in vitro experiments are required to confirm these findings.

Indexed as

Gene Expression Regulation, NeoplasticAdenocarcinomaComputational BiologyDatabases, GeneticDisease ProgressionDown-RegulationGene Expression ProfilingHumansMaleMicroRNAsMiddle AgedPrognosisProstatic NeoplasmsProtein Interaction MapsSignal TransductionSurvival RateMicroRNAsMIRN224 microRNA, human

Identifiers

PMID30542718
PMCPMC6196605
OpenAlexW2894548036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.